Anterogen Overview
- Founded
-
2000
- Status
-
Public
- Employees
-
41
- Stock Symbol
-
065660
- Share Price
-
$17.03
- (As of Friday Closing)
Anterogen General Information
Description
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Primary Office
- 345-30 Gasan-dong
- Geumcheon-gu
- Seoul, 08589
- South Korea
+82 00-0000-0000
Anterogen Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.03 | $16.53 | $15.13 - $88.78 | $161M | 9.7M | 62.1K | -$0.02 |
Anterogen Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 182,744 | 470,506 | 483,866 | 284,514 |
| Revenue | 7,110 | 7,090 | 3,516 | 3,557 |
| EBITDA | 394 | 1,026 | (3,059) | (2,796) |
| Net Income | (297) | (484) | (3,705) | (3,473) |
| Total Assets | 128,114 | 114,873 | 86,353 | 73,030 |
| Total Debt | 9,439 | 9,891 | 8,482 | 7,206 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Anterogen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anterogen Patents
Anterogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2020033377-A | Mesenchymal stem cell-hydrogel-biodegradability or mesenchymal stem cell-hydrogel-non-degradable support composition for alleviating or improving epidermolysis bullosa | Pending | 12-Apr-2016 | 0000000000 | |
| EP-3290028-A1 | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-nondegradable support composition for alleviating or remedying epidermolysis bullosa | Pending | 12-Apr-2016 | 00000000000 | |
| JP-2018515444-A | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-non-degradable support composition for alleviating or improving bullous epidermis | Granted | 12-Apr-2016 | 00000000000 | 0 |
| EP-3290028-A4 | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-nondegradable support composition for alleviating or remedying epidermolysis bullosa | Pending | 12-Apr-2016 | 0000000000 | 0 |
| JP-6810706-B2 | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-non-degradable support composition for alleviating or ameliorating bullous epidermal ablation | Active | 12-Apr-2016 | A61L27/3813 |
Anterogen Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Sung-Koo Lee | Co-Chief Executive Officer & Board Member | ||
| Lee Seong-gu | Co-Chief Executive Officer | ||
| Ike Wan Lee Ph.D | Chief Scientific Officer & Founder |
Anterogen Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Mi-hyung Kim | Anterogen | Board Member | 000 0000 |
| Sung-Koo Lee | Anterogen | Co-Chief Executive Officer & Board Member | 000 0000 |
Anterogen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Anterogen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|